Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Regenxbio (RGNX) over the last 11 years, with Q3 2025 value amounting to $34.4 million.

  • Regenxbio's Current Deferred Revenue rose 2378888.89% to $34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year increase of 2378888.89%. This contributed to the annual value of $115000.0 for FY2024, which is 2229.73% down from last year.
  • Per Regenxbio's latest filing, its Current Deferred Revenue stood at $34.4 million for Q3 2025, which was up 2378888.89% from $37.8 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Current Deferred Revenue registered a high of $39.9 million during Q1 2025, and its lowest value of $13000.0 during Q1 2024.
  • Its 5-year average for Current Deferred Revenue is $7.8 million, with a median of $3.3 million in 2021.
  • Per our database at Business Quant, Regenxbio's Current Deferred Revenue tumbled by 9900.84% in 2024 and then soared by 30682307.69% in 2025.
  • Regenxbio's Current Deferred Revenue (Quarter) stood at $3.3 million in 2021, then crashed by 45.12% to $1.8 million in 2022, then tumbled by 91.91% to $148000.0 in 2023, then fell by 22.3% to $115000.0 in 2024, then surged by 29813.04% to $34.4 million in 2025.
  • Its Current Deferred Revenue was $34.4 million in Q3 2025, compared to $37.8 million in Q2 2025 and $39.9 million in Q1 2025.